Eli Lilly has rolled out its Alzheimer’s therapy Lormalzi in India, announcing a list price of 91,688 rupees for a 350 mg vial - approximately $957 - the company said. The drug is the companys Donanemab formulation and is slated to reach commercial availability later this month.
Intended to be delivered as an intravenous infusion once every four weeks, the treatment targets amyloid plaques in the brain associated with the progression of Alzheimers disease. Lormalzi has secured marketing authorization from Indias Central Drugs Standard Control Organization for use in patients at the mild cognitive impairment or mild dementia stages of the illness.
In the United States, the same therapy received approval last year under the brand name Kisunla. The India launch follows earlier comments from a Lilly executive that signaled a larger role for the country in the companys global operations. According to those remarks, India is expected to serve increasingly as a manufacturing and export hub as Lilly expands its presence.
Winselow Tucker, president and general manager of Eli Lilly and Company (India), stated in February that the company intended to introduce additional products into the Indian market. The recent pricing and regulatory approval set the immediate commercial parameters for Lormalzis initial rollout in the country.
The announcement comprises the principal commercial details available ahead of the products market entry later this month: the therapys dosing and administration cadence, its approved patient population in India, and the per-vial list price. No additional launch logistics, reimbursement arrangements, or distribution specifics were provided in the announcement.
Observers and stakeholders will be watching how the listed price, approval scope limited to early-stage patients, and the timing of commercial availability influence uptake and access in India. The companys prior statements about expanding Indias role in manufacturing and exports suggest Lormalzi is part of a broader product strategy for the market.